Clinical Trial on the Effects of Bifidobacterium Infantis in Active Celiac Disease

Inclusion Criteria: * Signing the Informed consent. * Men or women, 18-75 years old. * BMI between 18.5 and 35. * Patients shall have a positive CD-related serology (combined positivity of DGP/tTG Screen plus IgA anti-tTG and or IgA a-DGP tests). * Patients will abstain from taking medications prohibited by the study from the 7 days prior the enrolment to the end of the trial: NSAIDs, aspirin, lactulose, probiotics and prebiotics in any form of administration (eg. Yogurts or other dairy products).. * Alcohol consumption is prohibited during the same period. * Patients should commit to attend on scheduled days, in accordance with the study calendar. * To be interested in participating the trial Exclusion Criteria: * Patients with refractory CD or severe complications thereof, enteropathy-associated T-cell Lymphoma (EATL), ulcerative jejunitis, perforation, severe osteoporosis, malnutrition, among others. * Individuals with symptoms suggestive of lymphoma or any other serious CD complication taking special care in recently-diagnosed patients, 50 years old or older, in whom EATL must be ruled out by standard methods. * Individuals with other active chronic GI pathologies like Crohn's disease, ulcerative colitis and irritable bowel syndrome, microscopic colitis, and lactose intolerance. * Patients with Type 1 or Type 2 diabetes or other autoimmune diseases, such as autoimmune hepatitis and primary biliary cirrhosis. * Individuals with co-morbidities whose participation, in the investigator's judgment, would be inadvisable; for instance, unstable clinical conditions such as chronic obstructive pulmonary disease, angina pectoris, severe cardio-respiratory conditions, etc. * Individuals with symptomatic neurological or psychiatric conditions that could potentially interfere with the study. * Individuals with a clinical severity requiring immediate treatment at the consideration of the investigator. * Patients with hemoglobin levels less than 8.5 g/dL or who had donated blood in the last 56 days or donated a unit of plasma in the last 7 days. * Patients with a history of alcohol or drug abuse in the prior 2 years. * Individuals taking "prohibited" medications in relation to the study (see point 6, previous section). * Individuals with a history of neoplasia. * Individuals participating in another clinical study that either involves medications or concluded during the last 30 days. * Individuals previously exposed to Bifidobacteria species. * Subjects not willing to maintain a gluten-containing diet during the 3-weeks period of the trial * Pregnant women. * Allergies to goat milk; no recent or planned dietary changes, esp. regarding gluten intake.